Skip to content

Cash In On This “Strong Buy” NASH Stock

In the wake of two seemingly negative events, shares of the nonalcoholic steatohepatitis (NASH) drug developer focused on in today’s article experienced a sharp sell-off at the end of last week, but one analyst is imploring investors to “view last week’s weakness as a prime buying opportunity” – and sees massive upside potential of 210%. For more on this stock – which boasts a “Strong Buy” consensus rating from analysts – CLICK HERE.